It is almost always a good idea for investors to start tracking stocks when they gain momentum and by that principle, the Synthetic Biologics Inc (NYSE: SYN) stock could be worth tracking.
The company is involved in developing therapies meant for treating and preventing gastrointestinal conditions. In recent times, the Synthetic Biologics stock has also managed to gain considerable momentum. On April 1, the company announced that enrolment has started for the Phase 1a clinical trial of its product SYN 020.
The product in question is intestinal alkaline phosphatase and is meant for oral delivery. More importantly, it has also been suggested by the company that it now has the capability of producing the SYN 020 at a viable cost and scale in order to facilitate commercial development. This is a highly important announcement from the company since it indicates that if the product is approved then the company has a commercially viable production process in place already.